Phthalimide → HCID 69248953, 화합물

HRID 1037550노트

반응식

HRID 1037550 반응식
[CH:1]1([C:4]2[C:12]([N:13]([CH2:18][CH2:19][CH2:20]O)[S:14]([CH3:17])(=[O:16])=[O:15])=[CH:11][C:10]3[C:6](=[C:7]([C:36]([NH:38][CH3:39])=[O:37])[N:8]([C:22]4[CH:27]=[CH:26][C:25]([NH:28][C:29]5[CH:34]=[CH:33][C:32]([F:35])=[CH:31][CH:30]=5)=[CH:24][CH:23]=4)[N:9]=3)[CH:5]=2)[CH2:3][CH2:2]1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.[C:59]1(=[O:69])[NH:63][C:62](=[O:64])[C:61]2=[CH:65][CH:66]=[CH:67][CH:68]=[C:60]12.N(C(OC(C)C)=O)=NC(OC(C)C)=O.CC(OC(/N=N/C(OC(C)C)=O)=O)C>C1COCC1>[CH:1]1([C:4]2[C:12]([N:13]([CH2:18][CH2:19][CH2:20][N:63]3[C:59](=[O:69])[C:60]4[C:61](=[CH:65][CH:66]=[CH:67][CH:68]=4)[C:62]3=[O:64])[S:14]([CH3:17])(=[O:16])=[O:15])=[CH:11][C:10]3[C:6](=[C:7]([C:36]([NH:38][CH3:39])=[O:37])[N:8]([C:22]4[CH:27]=[CH:26][C:25]([NH:28][C:29]5[CH:30]=[CH:31][C:32]([F:35])=[CH:33][CH:34]=5)=[CH:24][CH:23]=4)[N:9]=3)[CH:5]=2)[CH2:3][CH2:2]1

참가 물질

7

반응물 5

HCID 6809Phthalimide2회HCID 11776Triphenylphosphine2회HCID 75555Diisopropyl diazene-1,2-dicarboxylateHCID 5363146Diisopropyl azodicarboxylateHCID 675177915-Cyclopropyl-2-{4-[(4-fluorophenyl)amino]phenyl}-6-[(3-hydroxypropyl)(methylsulfonyl)amino]-N-methyl-2H-indazole-3-carboxamide

생성물 1

HCID 69248953HCID 69248953, 화합물수율 326.4%

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

실험 절차

To a solution of compound (ii) (5 mg, 0.009 mmol), triphenylphosphine (3.6 mg, 0.014 mmol) and phthalimide (2.0 mg, 0.014 mmol) in THF (0.5 mL) was added diisopropyl azodicarboxylate (2.7 μL, 0.014 mmol) at 0° C. After the mixture had been stirred at RT for 3.5 h, more triphenylphosphine (3.6 mg, 0.014 mmol), phthalimide (2.0 mg, 0.014 mmol) and DIAD (2.7 μL, 0.014 mmol) were added and stirring was continued at RT for a further 40 min. The solvent was removed in vacuo and the residue was purified by preparative LCMS (5-50-100% ACN in 0.1% aqueous formic acid) to afford 5-cyclopropyl-6-[3-(1,3-dioxoisoindolin-2-yl)propyl-methylsulfonyl-amino]-2-[4-(4-fluoroanilino)phenyl]-N-methyl-indazole-3-carboxamide (iii) as a white solid (20 mg, 81%).

후처리

  1. stirringstirring
  2. waitwas continued at RT for a further 40 min
  3. customThe solvent was removed in vacuo
  4. customthe residue was purified by preparative LCMS (5-50-100% ACN in 0.1% aqueous formic acid)

출처 및 근거

ORD 기록
ord-8ca34f4bf575488a866f72b1f841972f
출처 데이터셋
uspto-grants-2013_10
특허 번호
US08546389B2

반응 노트

불러오는 중…